Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation

Michael Kreuter, Markus Polke, Simon L.F. Walsh, Johannes Krisam, Harold R. Collard, Nazia Chaudhuri, Sergey Avdeev, Jürgen Behr, Gregory Calligaro, Tamera Corte, Kevin Flaherty, Manuela Funke-Chambour, Martin Kolb, Yasuhiro Kondoh, Toby M. Maher, Maria Molina Molina, Antonio Morais, Catharina C. Moor, Julie Morisset, Carlos Pereira, Silvia Quadrelli, Moises Selman, Argyrios Tzouvelekis, Claudia Valenzuela, Carlo Vancheri, Vanesa Vicens-Zygmunt, Julia Wälscher, Wim Wuyts, Marlies Wijsenbeek, Vincent Cottin, Elisabeth Bendstrup
European Respiratory Journal 2020 55: 1901760; DOI: 10.1183/13993003.01760-2019
Michael Kreuter
1Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
2Member of the German Center for Lung Research (DZL), Germany
36Equal contribution
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kreuter@uni-heidelberg.de
Markus Polke
1Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
36Equal contribution
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon L.F. Walsh
3National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Krisam
4Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold R. Collard
5Dept of Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazia Chaudhuri
6North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey Avdeev
7Sechenov First Moscow State Medical University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Behr
8Dept of Internal Medicine V, Ludwig-Maximilians University of Munich, Munich, Germany
9Asklepios Clinic Gauting, Member of the German Center for Lung Research, Gauting, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Calligaro
10Division of Pulmonology, Dept of Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory Calligaro
Tamera Corte
11Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Flaherty
12Dept of Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Funke-Chambour
13Dept of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
14Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Kolb
Yasuhiro Kondoh
15Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toby M. Maher
16National Heart and Lung Institute, Imperial College London, UK
17Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Molina Molina
18Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
19Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Morais
20Pneumology Dept, Centro Hospitalar São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Morais
Catharina C. Moor
21Centre for Interstitial Lung Diseases and Sarcoidosis, Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Morisset
22Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Pereira
23Lung Disease Dept, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Quadrelli
24Hospital Británico, Buenos Aires, Argentina
25Sanatorio Güemes, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moises Selman
26Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Tlalpan, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Moises Selman
Argyrios Tzouvelekis
27First Academic Respiratory Dept, Sotiria General Hospital for Thoracic Diseases, University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Valenzuela
28Instituto de Investigación Princesa, Hospital Universitario de La Princesa, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Vancheri
29Regional Referral Centre for Rare Lung Diseases, A.O.U. Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanesa Vicens-Zygmunt
30Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
31Unit of Interstitial Lung Diseases, Department of Pneumology, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Wälscher
1Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Wuyts
32Unit for Interstitial Lung Diseases, Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wim Wuyts
Marlies Wijsenbeek
21Centre for Interstitial Lung Diseases and Sarcoidosis, Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
37Shared senior authorship
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Cottin
33National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France
34Hospices Civils de Lyon, UMR754, University Claude Bernard Lyon 1, Lyon, France
37Shared senior authorship
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Cottin
Elisabeth Bendstrup
35Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus C, Denmark
37Shared senior authorship
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an often deadly complication of IPF. No focussed international guidelines for the management of AE-IPF exist. The aim of this international survey was to assess the global variability in prevention, diagnostic and treatment strategies for AE-IPF.

Pulmonologists with ILD expertise were invited to participate in a survey designed by an international expert panel.

509 pulmonologists from 66 countries responded. Significant geographical variability in approaches to manage AE-IPF was found. Common preventive measures included antifibrotic drugs and vaccination. Diagnostic differences were most pronounced regarding use of Krebs von den Lungen-6 and viral testing, while high-resolution computed tomography, brain natriuretic peptide and D-dimer are generally applied. High-dose steroids are widely administered (94%); the use of other immunosuppressant and treatment strategies is highly variable. Very few (4%) responders never use immunosuppression. Antifibrotic treatments are initiated during AE-IPF by 67%. Invasive ventilation or extracorporeal membrane oxygenation are mainly used as a bridge to transplantation. Most physicians educate patients comprehensively on the severity of AE-IPF (82%) and consider palliative care (64%).

Approaches to the prevention, diagnosis and treatment of AE-IPF vary worldwide. Global trials and guidelines to improve the prognosis of AE-IPF are needed.

Abstract

Lack of focussed international guidelines for management of acute exacerbation of IPF results in global variability in prevention, diagnosis and treatment strategies. Global trials are urgently needed to inform international specific guidelines for AE-IPF. http://bit.ly/3a8FB5i

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Conflict of interest: M. Kreuter reports grants and personal fees from Roche, Galapagos and Boehringer, outside the submitted work.

  • Conflict of interest: M. Polke has nothing to disclose.

  • Conflict of interest: S.L.F. Walsh reports personal fees for consultancy from Sanofi-Aventis, Galapagos and OSIC, personal fees for advisory board work from Roche, grants and personal fees for steering committee work from Boehringer Ingelheim, personal fees for lectures from Bracco, outside the submitted work.

  • Conflict of interest: J. Krisam has nothing to disclose.

  • Conflict of interest: H.R. Collard reports personal fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Global Blood Therapeutics, ImmuneWorks, Navitor, Parexel, Prometic, Toray, Unity, Patara, Veracyte, Roche/Genentech, aTyr, Advance Medical and MedImmune, grants from Pulmonary Fibrosis Foundation, grants and personal fees from Three Lakes Partners, outside the submitted work.

  • Conflict of interest: N. Chaudhuri reports grants from Boehringer Ingelheim and Roche, educational support from Boehringer Ingelheim and Roche, outside the submitted work.

  • Conflict of interest: S. Avdeev has nothing to disclose.

  • Conflict of interest: J. Behr has nothing to disclose.

  • Conflict of interest: G. Calligaro has nothing to disclose.

  • Conflict of interest: T. Corte reports grants, personal fees for lectures and advisory board work, and travel support from Boehringer, grants and personal fees for lectures and advisory board work from Roche, grants from Galapagos, Actelion, Bayer and Sanofi, personal fees for advisory board work from AstraZeneca, outside the submitted work.

  • Conflict of interest: K. Flaherty reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech, personal fees from Bellerophon, Respivant, Veracyte, Sanofi-Genzyme, Blade Therapeutics and Celgene, outside the submitted work.

  • Conflict of interest: M Funke-Chambour has nothing to disclose.

  • Conflict of interest: M. Kolb reports grants and personal fees for consultancy and lectures from Roche and Boehringer Ingelheim, grants and personal fees for consultancy from GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, personal fees for consultancy from Genoa, Indalo and Third Pole, outside the submitted work.

  • Conflict of interest: Y. Kondoh reports advisory board fees and lecture fees from Asahi Kasei Pharma Corp. and Boehringer Ingelheim Co., Ltd, advisory board fees from Janssen Pharmaceutical K.K., lecture fees from Eisai Inc., Kyorin Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma, Novartis Pharma K.K. and Shionogi and Co., Ltd, outside the present work.

  • Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB, and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R& D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB.

  • Conflict of interest: M. Molina Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, grants from GSK and AstraZeneca, personal fees from Pfizer and Chiesi, outside the submitted work.

  • Conflict of interest: A. Morais has nothing to disclose.

  • Conflict of interest: C.C. Moor has nothing to disclose.

  • Conflict of interest: J. Morisset reports personal fees from Hoffmann La Roche and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: C. Pereira has nothing to disclose.

  • Conflict of interest: S. Quadrelli has nothing to disclose.

  • Conflict of interest: M. Selman has nothing to disclose.

  • Conflict of interest: A. Tzouvelekis has nothing to disclose.

  • Conflict of interest: C. Valenzuela reports personal fees for advisory board work and lectures from Roche and Boehringer Ingelheim, personal fees for advisory board work from Galapagos, outside the submitted work.

  • Conflict of interest: C. Vancheri reports grants and personal fees from Roche and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: V. Vicens-Zygmunt has nothing to disclose.

  • Conflict of interest: J. Wälscher has nothing to disclose.

  • Conflict of interest: W. Wuyts has nothing to disclose.

  • Conflict of interest: M. Wijsenbeek reports grants and fees paid to institution from Boehringer Ingelheim and Hoffman la Roche, fees paid to institution from Galapagos and Novartis, outside the submitted work.

  • Conflict of interest: V. Cottin reports personal fees for advisory board work and lectures, and non-financial (travel) support from Actelion, grants, personal fees for consultancy and lectures, and non-financial (travel) support from Boehringer Ingelheim and Roche, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for adjudication committee work from Gilead, personal fees for advisory board work and lectures from Novartis, personal fees for lectures from Sanofi, personal fees for data monitoring and steering committee work from Promedior, personal fees for data monitoring committee work from Celgene and Galecto, outside the submitted work.

  • Conflict of interest: E. Bendstrup reports grants and personal fees from Boehringer Ingelheim and Roche, outside the submitted work.

  • Received September 6, 2019.
  • Accepted January 6, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 4 Table of Contents
European Respiratory Journal: 55 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Michael Kreuter, Markus Polke, Simon L.F. Walsh, Johannes Krisam, Harold R. Collard, Nazia Chaudhuri, Sergey Avdeev, Jürgen Behr, Gregory Calligaro, Tamera Corte, Kevin Flaherty, Manuela Funke-Chambour, Martin Kolb, Yasuhiro Kondoh, Toby M. Maher, Maria Molina Molina, Antonio Morais, Catharina C. Moor, Julie Morisset, Carlos Pereira, Silvia Quadrelli, Moises Selman, Argyrios Tzouvelekis, Claudia Valenzuela, Carlo Vancheri, Vanesa Vicens-Zygmunt, Julia Wälscher, Wim Wuyts, Marlies Wijsenbeek, Vincent Cottin, Elisabeth Bendstrup
European Respiratory Journal Apr 2020, 55 (4) 1901760; DOI: 10.1183/13993003.01760-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Michael Kreuter, Markus Polke, Simon L.F. Walsh, Johannes Krisam, Harold R. Collard, Nazia Chaudhuri, Sergey Avdeev, Jürgen Behr, Gregory Calligaro, Tamera Corte, Kevin Flaherty, Manuela Funke-Chambour, Martin Kolb, Yasuhiro Kondoh, Toby M. Maher, Maria Molina Molina, Antonio Morais, Catharina C. Moor, Julie Morisset, Carlos Pereira, Silvia Quadrelli, Moises Selman, Argyrios Tzouvelekis, Claudia Valenzuela, Carlo Vancheri, Vanesa Vicens-Zygmunt, Julia Wälscher, Wim Wuyts, Marlies Wijsenbeek, Vincent Cottin, Elisabeth Bendstrup
European Respiratory Journal Apr 2020, 55 (4) 1901760; DOI: 10.1183/13993003.01760-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Identifying asthma phenotypes based on extrapulmonary traits
  • Upregulation of the Mas receptor and sex differences in acute lung injury
  • OSTEOPOROSIS AND FRAGILITY FRACTURES IN ASTHMA
Show more Original Articles

Interstitial lung disease

  • Pirfenidone plus inhaled NAC for IPF
  • Exhaled breath analysis by use of eNose technology
  • Interstitial lung abnormalities, cancer diagnoses and mortality
Show more Interstitial lung disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society